Tonix director granted 22,700 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tonix Pharmaceuticals Holding Corp. director James Treco received a grant of stock options as part of equity compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share, expiring in 2036.
The options were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the May 12, 2026 grant date or the company’s 2027 Annual Meeting of Stockholders. Following this award, Treco holds options for 22,700 shares directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 22,700 | $0.00 | $0.00 |
Footnotes (1)
- F1. The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.
Key Figures
Key Terms
Stock Option financial
2026 Stock Incentive Plan financial
Annual Meeting of Stockholders financial
Grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tonix Pharmaceuticals (TNXP) director James Treco report on this Form 4?
What is the exercise price and expiration date of James Treco’s Tonix (TNXP) stock options?
When do James Treco’s Tonix Pharmaceuticals (TNXP) stock options vest?
Were James Treco’s Tonix (TNXP) stock options an open-market purchase?
AI-generated analysis. How Rhea-AI works. Not financial advice.